Biogen (BIIB) Return on Capital Employed (2009 - 2026)
Biogen (BIIB) posted quarterly Return on Capital Employed of 5.94% for Q2 2026, down 331.0% year-over-year from 2.57% in Q2 2025, and down 93.42% quarter-over-quarter from 3.07% in Q1 2026.
Biogen (BIIB) Return on Capital Employed (2009 - 2026) Analysis & Trends
Biogen's Return on Capital Employed history runs 18 years deep, the most recent figure standing at 5.94% for Q2 2026.
- In Q2 2026, Return on Capital Employed fell 331.0% year-over-year to 5.94%; the TTM figure through Jun 2026 stood at 5.94% (down 331.0% YoY), while the FY2025 annual figure was 3.34%, down 149.0% from the prior year.
- Return on Capital Employed for Q2 2026 stood at 5.94%, down from 3.07% in the prior quarter.
- The five-year high for Return on Capital Employed was 14.37% in Q2 2022, with the low at 5.94% in Q2 2026.
- The 5-year median for Return on Capital Employed is 2.24% (2023), against an average of 1.97%.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed surged 406 bps in 2022, then slumped 1602 bps in 2023.
- Biogen's Return on Capital Employed stood at 12.77% in 2022, then tumbled by 125 bps to 3.25% in 2023, then jumped by 45 bps to 1.79% in 2024, then slumped by 83 bps to 3.26% in 2025, then sank by 82 bps to 5.94% in 2026.
- Business Quant data shows BIIB's Return on Capital Employed at 5.94% in Q2 2026, 3.07% in Q1 2026, and 3.26% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 17.83% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 17.92% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.96% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 16.76% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 16.66% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -5.97% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.86% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 11.42% |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | -5.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.94% |
| Mar 31, 2026 | -3.07% |
| Dec 31, 2025 | -3.26% |
| Sep 30, 2025 | -2.31% |
| Jun 30, 2025 | -2.64% |
| Mar 31, 2025 | -2.84% |
| Dec 31, 2024 | -1.79% |
| Sep 30, 2024 | 0.07% |
| Jun 30, 2024 | -2.54% |
| Mar 31, 2024 | -2.70% |
| Dec 31, 2023 | -3.25% |
| Sep 30, 2023 | -2.17% |
| Jun 30, 2023 | 5.68% |
| Mar 31, 2023 | 8.82% |
| Dec 31, 2022 | 12.77% |
| Sep 30, 2022 | 13.71% |
| Jun 30, 2022 | 14.37% |
| Mar 31, 2022 | 12.51% |
| Dec 31, 2021 | 14.54% |
| Sep 30, 2021 | 9.65% |